Tirzepatide for young adults with obesity
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests the diabetes/weight-loss drug tirzepatide (Mounjaro) in young adults aged 18–26 who have obesity and either Prader-Willi syndrome, hypothalamic obesity, or general obesity. It looks at whether a weekly injection can help with weight management.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–26 and obesity (BMI ≥30 or above the 95th percentile for your age and sex).
- Have one of these conditions: Prader-Willi syndrome (genetically confirmed), hypothalamic obesity (damage to the brain's appetite center), or general obesity not linked to a genetic disorder.
- Stable lifestyle (diet, exercise, living situation) for at least the last 6 months.
- No weight-loss medications in the past 3 months and no GLP-1 or DPP-4 drugs in the past 6 months.
- Not pregnant or nursing, and willing to use birth control if you could become pregnant.
- No recent significant weight changes (more than 3% up or down in the last 2 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called tirzepatide (a once-weekly injection) to help teenagers with obesity and related health conditions lose weight. It aims to see if the drug is safe and effective for this age group.
This study tests a medicine called tirzepatide to see if it helps people with overweight or obesity lose weight, whether or not they also have type 2 diabetes. Tirzepatide is given as an injection and works on hormones that control appetite.
This study tests a once-weekly medication called tirzepatide to help children aged 6 to under 12 with obesity lose weight. It compares the medication to a placebo (inactive shot) to see if it safely helps with weight loss in this age group.
This trial tests if tirzepatide is more effective than standard obesity treatments for adults who have a BMI between 30 and 35 and one weight-related health condition, but do not have diabetes. The goal is to help you lose weight.
This study looks at how well the medicine tirzepatide works in real life for adults who are overweight (BMI 30 or more) and have prediabetes or type 2 diabetes. It aims to see if the medicine helps control blood sugar and weight, and it's important that you have had a recent eye exam before starting.
This study tests a weekly injection called tirzepatide to help people with obesity lose weight. It will be done at Hospital de Clínicas in Paraguay and lasts about 12 months.
Hear when a new Prader-Willi Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.